Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374484 | 0.86 | NPC1 (0.41) | CYP1A2CYP2C19KDM4EHPGDNPSR1 | |
| SCHEMBL8133581 | 0.86 | KDM4E (0.51) | CYP1A2CYP2C19KDM4EHPGDNPSR1 | |
| SCHEMBL743993 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2C19KDM4EHPGDNPSR1 | |
| SCHEMBL2214803 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP2C19KDM4EHPGDNPSR1 | |
| SCHEMBL11941733 | 0.83 | ALDH1A1 (0.41) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL15849614 | 0.82 | CYP1A2 (0.39) | CYP1A2CYP2C19KDM4EHPGDNPSR1 | |
| SCHEMBL12468515 | 0.81 | CYP2D6 (0.41) | CYP1A2CYP2C19KDM4EHPGDNPSR1 | |
| SCHEMBL6810272 | 0.81 | KDM4E (0.46) | CYP1A2CYP2C19KDM4EHPGDNPSR1 | |
| SCHEMBL10220200 | 0.81 | KDM4E (0.41) | CYP1A2CYP2C19KDM4EHPGDNPSR1 | |
| SCHEMBL10271446 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP2C19KDM4EHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1906945-B1 | HCV INHIBITORS | VIROBAY INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8809266-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8518874-B2 | HCV inhibitors | VIROBAY, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518874-B2 | HCV inhibitors | VIROBAY, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518874-B2 | HCV inhibitors | VIROBAY, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1169339-B1 | MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE | BOEHRINGER INGELHEIM CA LTD (CA) | 2004-09-29 | — | — | EP | disclosed |
| EP-1437362-A1 | Macrocyclic peptides inhibiting the hepatitis C virus ns3 protease | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-07-14 | — | — | EP | disclosed |
| US-20040002448-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-01-01 | — | — | US | disclosed |
| US-6608027-B1 | Macrocyclic small peptides of low molecular weight that are inhibitory to NS3 protease of hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2003-08-19 | — | — | US | disclosed |
| EP-1169339-A1 | MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000059929-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP1A2 3826/4885CYP2C19 3298/4885KDM4E 2496/4885 |
| US-20040002448-A1 | Macrocyclic peptides active against the hepatitis C virus | VIP, FURIN, RNASE1 | CYP1A2 1886/4885CYP2C19 599/4885KDM4E 3584/4885 |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | HAVCR2, EIF2AK2, GTF3C1 | CYP1A2 505/4885CYP2C19 1367/4885KDM4E 536/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP1A2 3826/4885CYP2C19 3298/4885KDM4E 2496/4885 |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP1A2 3826/4885CYP2C19 3298/4885KDM4E 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.